Ogeda

Ogeda (formerly known as Euroscreen) is a privately-held, clinical-stage drug discovery and development company based in Belgium, primarily focusing on small molecule drug candidates targeting GPCRs. Ogeda's orally available, proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase II clinical development for the treatment of women’s health disorders. Ogeda has more small molecule drugs targeting GPCRs in preclinical development across multiple therapeutic areas, including inflammation and autoimmune diseases.